Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apatinib combined with oral etoposide in patients as second- or later-line with triple negativebreast cancer: a phase II, single-arm, prospective study

Next Previous
Search
Trial Profile

Apatinib combined with oral etoposide in patients as second- or later-line with triple negativebreast cancer: a phase II, single-arm, prospective study

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Etoposide (Primary) ; Rivoceranib (Primary)
  • Indications Advanced breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 07 Jun 2022 Results investigating the potential effect of combination therapy of apatinib plus etoposide in recurrent or metastatic TNBC, presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 14 Dec 2019 Status changed from recruiting to active, no longer recruiting, according to results presented at the 42nd Annual San Antonio Breast Cancer Symposium.
    • 14 Dec 2019 Results presented at the 42nd Annual San Antonio Breast Cancer Symposium

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top